Literature DB >> 28349291

Preliminary PET/CT Imaging with Somatostatin Analogs [68Ga]DOTAGA-TATE and [68Ga]DOTAGA-TOC.

Drishty Satpati1, Ajit Shinto2, K K Kamaleshwaran2, Haladhar Dev Sarma3, Ashutosh Dash4.   

Abstract

PURPOSE: Somatostatin receptor positron emission tomography/X-ray computed tomography (SSTR-PET/CT) is a well-established technique for staging and detection of neuroendocrine tumors (NETs). Ga-68-labeled DOTA-conjugated octreotide analogs are the privileged radiotracers for diagnosis and therapeutic monitoring of NETs. Hence, we were interested in assessing the influence of promising, newer variant DOTAGA on the hydrophilicity, pharmacokinetics, and lesion pick-up of somatostatin analogs. Herein, the potential of ([68Ga]DOTAGA, Tyr3, Thr8) octreotide ([68Ga]DOTAGA-TATE) and ([68Ga]DOTAGA, Tyr3) octreotide ([68Ga]DOTAGA-TOC) as NET imaging agents has been investigated. PROCEDURES: Amenability of [68Ga]DOTAGA-(TATE/TOC) to kit-type formulation has been demonstrated. Biodistribution studies were carried out in normal rats at 1 h post-injection (p.i.). [68Ga]DOTAGA-(TATE/TOC) PET/CT scans were carried out in patients (70-170 MBq, 1 h p.i.) with histologically confirmed well-differentiated NETs.
RESULTS: [68Ga]DOTAGA-TATE exhibited hydrophilicity similar to [68Ga]DOTA-TATE (log P = -3.51 vs -3.69) whereas [68Ga]DOTAGA-TOC was more hydrophilic than [68Ga]DOTA-TOC (log P = -3.27 vs -2.93). [68Ga]DOTAGA-TATE and [68Ga]DOTA-TATE showed almost identical blood and kidney uptake in normal rats whereas significantly fast clearance (p < 0.05) of [68Ga]DOTAGA-TATE was observed from other non-specific organs (liver, lungs, spleen, intestine). [68Ga]DOTAGA-TOC also demonstrated rapid clearance from blood and kidneys (p < 0.05) in comparison to [68Ga]DOTA-TOC. The metastatic lesions in NET patients were well identified by [68Ga]DOTAGA-TATE and [68Ga]DOTAGA-TOC.
CONCLUSION: The phenomenal analogy was observed between [68Ga]DOTAGA-TATE and [68Ga]DOTA-TATE as well as between [68Ga]DOTAGA-TOC and [68Ga]DOTA-TOC in biodistribution studies in rats. The good lesion detection ability of the two radiotracers indicates their potential as NET imaging radiotracers.

Entities:  

Keywords:  Neuroendocrine tumor; SSTR-PET/CT; [68Ga]DOTAGA-TATE; [68Ga]DOTAGA-TOC

Mesh:

Substances:

Year:  2017        PMID: 28349291     DOI: 10.1007/s11307-017-1072-z

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  28 in total

1.  Be spoilt for choice with radiolabelled RGD peptides: preclinical evaluation of ⁶⁸Ga-TRAP(RGD)₃.

Authors:  Johannes Notni; Karolin Pohle; Hans-Jürgen Wester
Journal:  Nucl Med Biol       Date:  2012-09-18       Impact factor: 2.408

2.  Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.

Authors:  Kristina Westerlund; Hadis Honarvar; Emily Norrström; Joanna Strand; Bogdan Mitran; Anna Orlova; Amelie Eriksson Karlström; Vladimir Tolmachev
Journal:  Mol Pharm       Date:  2016-04-06       Impact factor: 4.939

3.  68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.

Authors:  Michael Gabriel; Clemens Decristoforo; Dorota Kendler; Georg Dobrozemsky; Dirk Heute; Christian Uprimny; Peter Kovacs; Elisabeth Von Guggenberg; Reto Bale; Irene J Virgolini
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

4.  Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation.

Authors:  Michael S Hofman; W F Eddie Lau; Rodney J Hicks
Journal:  Radiographics       Date:  2015 Mar-Apr       Impact factor: 5.333

5.  Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study.

Authors:  Yaping Luo; Qingqing Pan; Shaobo Yao; Miao Yu; Wenming Wu; Huadan Xue; Dale O Kiesewetter; Zhaohui Zhu; Fang Li; Yupei Zhao; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2016-01-21       Impact factor: 10.057

6.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

Authors:  A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-24       Impact factor: 9.236

7.  Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK).

Authors:  Jakub Simeček; Johannes Notni; Tobias G Kapp; Horst Kessler; Hans-Jürgen Wester
Journal:  Mol Pharm       Date:  2014-04-04       Impact factor: 4.939

8.  Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer.

Authors:  Martina Weineisen; Jakub Simecek; Margret Schottelius; Markus Schwaiger; Hans-Jürgen Wester
Journal:  EJNMMI Res       Date:  2014-11-25       Impact factor: 3.138

9.  [(68)Ga]NODAGA-RGD - Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis.

Authors:  Roland Haubner; Armin Finkenstedt; Armin Stegmayr; Christine Rangger; Clemens Decristoforo; Heinz Zoller; Irene J Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-05-11       Impact factor: 9.236

10.  Twins in spirit - episode I: comparative preclinical evaluation of [(68)Ga]DOTATATE and [(68)Ga]HA-DOTATATE.

Authors:  Margret Schottelius; Jakub Šimeček; Frauke Hoffmann; Marina Willibald; Markus Schwaiger; Hans-Jürgen Wester
Journal:  EJNMMI Res       Date:  2015-04-10       Impact factor: 3.138

View more
  4 in total

1.  Primary neuroendocrine tumor in the presacral region: A case report.

Authors:  Rui Zhang; Yong Zhu; Xiao-Bo Huang; Chris Deng; Min Li; Guang-Shu Shen; Shu-Liang Huang; Shao-Hua Huangfu; Yan-Ni Liu; Chun-Gen Zhou; Ling Wang; Qi Zhang; Youping Deng; Bin Jiang
Journal:  World J Clin Cases       Date:  2019-07-26       Impact factor: 1.337

Review 2.  Cold Kit Labeling: The Future of 68Ga Radiopharmaceuticals?

Authors:  Nicolas Lepareur
Journal:  Front Med (Lausanne)       Date:  2022-02-10

Review 3.  Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [64Cu]Cu-DOTA-TOC.

Authors:  Nasim Vahidfar; Saeed Farzanehfar; Mehrshad Abbasi; Siroos Mirzaei; Ebrahim S Delpassand; Farzad Abbaspour; Yalda Salehi; Hans Jürgen Biersack; Hojjat Ahmadzadehfar
Journal:  Cancers (Basel)       Date:  2022-04-10       Impact factor: 6.575

Review 4.  Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy.

Authors:  Alberto Signore; Chiara Lauri; Sveva Auletta; Michela Varani; Livia Onofrio; Andor W J M Glaudemans; Francesco Panzuto; Paolo Marchetti
Journal:  Cancers (Basel)       Date:  2020-03-25       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.